VolitionRx Limited to Present at Multiple Investor Conferences in June
NAMUR, Belgium, May 26, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it is scheduled to present at multiple investor conferences in June.
Dr. Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's product launch of its Nu.QTM Colorectal Cancer Screening Triage Test.
Details of the conferences are as follows
|
Conference: |
6th Annual SeeThruEquity Microcap Investor Conference |
|
Date: |
Thursday, June 1, 2017 |
|
Location: |
Convene Conference Center, New York, NY |
|
Conference: |
LD Micro Invitational |
|
Date: |
Wednesday, June 7, 2017 |
|
Time: |
10:30 a.m. PDT |
|
Location: |
Luxe Sunset Bel Air Hotel, Los Angeles, CA |
|
Conference: |
2017 Marcum MicroCap Conference |
|
Date: |
Friday, June 16, 2017 |
|
Time: |
10:00 a.m. EDT |
|
Location: |
Grand Hyatt Hotel, New York, NY |
Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com or Scott Powell, Executive Vice President of Volition, at S.Powell@volitionrx.com.
About Volition
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
|
Louise Day, Volition +44 (0)7557 774620 |
Scott Powell, Volition +1 (646) 650 1351 |
|
Tirth Patel, Edison Advisors +1 (646) 653 7035 |
Rachel Carroll, Edison Advisors +44 (0)20 3077 5711 |
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-multiple-investor-conferences-in-june-300464334.html
SOURCE VolitionRx Limited
Released May 26, 2017
